Study of NN3201 for Advanced c-Kit Expressing Solid Tumors
This study is testing a new treatment called NN3201 for people with advanced or metastatic (spread to other parts of the body) solid tumors that express c-Kit. NN3201 is an antibody-drug conjugate, which means it's designed to deliver a powerful drug directly to cancer cells that have a specific marker called c-Kit. The main goal of this study is to find out how safe NN3201 is and what side effects it might cause. You could be eligible if you have certain types of cancer like gastrointestinal stromal tumors (GIST), small-cell lung cancer (SCLC), adenoid cystic carcinoma (ACC), uveal melanoma, or neuroendocrine tumors (NET), and have already received some treatments. The study plans to enroll 67 participants.
- Study design
- This is an open-label study, meaning both you and your doctors will know which treatment you are receiving. It will involve about 67 participants and has two parts: a dose escalation phase and an expansion phase.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track adverse events (side effects) for up to 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
At a glance
Conditions
Where it's being run
5 sites across 5 statesStudy leadership
- Sunil Sharma, MD · PRINCIPAL_INVESTIGATOR · Novelty Nobility
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of subjects with Dose-limiting Toxicities:3 weeks
A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0 and is considered by the investigator to be clinically relevant and attributed to the study treatment during the first 21 days after the first dose of study treatment.
- Incidence of Adverse Events:1 year
Number of subjects with adverse events (AEs) according to severity, seriousness, and relationship to study drug